The COVID-19 Virus Outbreak is the third outbreak in the last two decades caused by the Corona virus and has resulted in global health problems. Following up on conditions during the pandemic, especially related to the resilience of health products for handling pandemics, the Ministry of Health encourages cooperation and synergism from various parties, namely academics / researchers, health sector industries, and the government to produce domestically produced COVID-19 handling products.

The Ministry of Health is making efforts to Transform the Health System, which includes increasing the resilience of the pharmaceutical sector, namely meeting the needs of chemical raw materials / active pharmaceutical ingredients (API), biological products, vaccines and natural (phytopharmaca) from domestic production and increasing their utilization in the country as well as exports.

The Directorate General of Pharmaceuticals and Medical Devices through the Directorate of Pharmaceutical and Medical Device Resilience conducted a Focus Group Discussion (FGD) Mapping of Domestic Vaccine Development to discuss strategies for accelerating the development and production of domestic vaccines, regulations and policies for accelerating the development of domestic vaccines, tax incentives for industry in domestic vaccine development, integration of research results as big data for domestic vaccine production development, and legal aspects of Intellectual Property Rights for researchers at research institutions.

The activity which was held on June 17, 2022 at the Mercure Hotel was carried out online and offline while still observing health protocols and was opened by the Director General of Pharmaceuticals and Medical Devices Lucia Rizka Andalucia. In her remarks, she said that in realizing the resilience and independence of medical devices, it cannot be done only from the government side, but also requires joint efforts and active participation from all relevant stakeholders, including researchers, innovators, research institutions, and the health industry.

“I hope that the national pharmaceutical industry will continue to work and innovate to produce domestically produced vaccines, the work of the nation's children.” ungkap Dirjen Farmalkes.

In addition to discussing the mapping, the results of which will be used in determining the baseline for the achievement of the IKK of the Directorate General of Pharmaceuticals and Medical Devices, this activity also discussed the refocussing/auto adjustment of the budget of the Directorate of Pharmaceutical and Medical Device Resilience.